<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04687813</url>
  </required_header>
  <id_info>
    <org_study_id>FTP198-102</org_study_id>
    <nct_id>NCT04687813</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of FTP-198 Tablet in Healthy Chinese Volunteers</brief_title>
  <acronym>FTP-198</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of FTP 198 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haisco Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haisco Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, single-dose escalation clinical trial for FTP-198 conducted in chinese&#xD;
      healthy volunteers. The safety, tolerability, food-impact and pharmacokinetics of FTP-198&#xD;
      tablet in healthy volunteers will be evaluated using a randomized, double-blind,&#xD;
      placebo-controlled trial design.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2020</start_date>
  <completion_date type="Anticipated">March 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double (Participant, Investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The number and severity of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>7 days after the last doses</time_frame>
    <description>To assess the safety and tolerability of single and multiple ascending oral doses of FTP-198 in healthy Chinese subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The level of changes of pharmacodynamic biomarkers</measure>
    <time_frame>within 0.5 hours before administration until 24 hours (single dose) or 48 hours (multiple doses) after administration</time_frame>
    <description>The change-from-baseline values of plasma lysophosphatidic acid (LPA) as PD biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>within 0.5 hours before administration until 48 hours after administration</time_frame>
    <description>peak palsma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>within 0.5 hours before administration until 48 hours after administration</time_frame>
    <description>area under the plasma concentration versus time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>within 0.5 hours before administration until 48 hours after administration</time_frame>
    <description>half-life</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single Ascending Doses 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: FTP-198, single dose 100mg Drug: Placebo, single dose Placebo matched to FTP-198, tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Doses 300mg(food-impact)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: FTP-198, single dose 300mg Drug: Placebo, single dose Placebo matched to FTP-198, tablet 2-X: fasting (Period 1) ; 2-Y:Postprandial (Period 1) 2-X:Postprandial (Period 2); 2-Y:fasting (Period 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Doses 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: FTP-198, single dose 600mg Drug: Placebo, single dose Placebo matched to FTP-198, tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is a tablet with the same appearance as FTP-198</description>
    <arm_group_label>Single Ascending Doses 100mg</arm_group_label>
    <arm_group_label>Single Ascending Doses 300mg(food-impact)</arm_group_label>
    <arm_group_label>Single Ascending Doses 600mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers will be included in Part A or Part B of the study if they satisfy&#xD;
             all the following criteria:&#xD;
&#xD;
               1. Must have given written informed consent before any study-related activities are&#xD;
                  carried out and must be able to understand the full nature and purpose of the&#xD;
                  trial, including possible risks and adverse effects;&#xD;
&#xD;
               2. Adult males and females, 18 to 55 years of age (inclusive) at screening;&#xD;
&#xD;
               3. Body mass index ≥ 18.0 and ≤ 30.0 kg/m2, with a body weight ≥ 50 kg at screening;&#xD;
&#xD;
               4. Be nonsmokers (including tobacco, e-cigarettes and marijuana) for at least 1&#xD;
                  month prior to first study drug administration;&#xD;
&#xD;
               5. Medically healthy without clinically significant abnormalities at screening and&#xD;
                  predose on Day 1, including:&#xD;
&#xD;
                    1. Physical examination without any clinically relevant findings;&#xD;
&#xD;
                    2. Systolic blood pressure in the range of 90 to 160 mmHg and diastolic blood&#xD;
                       pressure in the range of 50 to 95 mmHg after 5 minutes in supine position;&#xD;
&#xD;
                    3. Heart rate in the range of 50 to 100 bpm after 5 minutes rest in supine&#xD;
                       position;&#xD;
&#xD;
                    4. Body temperature, between 35.0°C and 37.5°C;&#xD;
&#xD;
                    5. No clinically significant findings in serum chemistry, hematology,&#xD;
                       coagulation and urinalysis tests as judged by the investigator;&#xD;
&#xD;
               6. Conventional 12-lead ECG recording in triplicate (the mean of triplicate&#xD;
                  measurements will be used to determine eligibility at screening and predose on&#xD;
                  Day 1) consistent with normal cardiac conduction and function, including:&#xD;
&#xD;
                    -  Normal sinus rhythm with HR between 50 and 100 bpm, inclusive;&#xD;
&#xD;
                    -  QT interval corrected using the Fridericia method (QTcF) between 350 to 450&#xD;
                       msec for male subjects and 350 to 470 msec for female subjects, inclusive;&#xD;
&#xD;
                    -  QRS duration of &lt; 120 msec;&#xD;
&#xD;
                    -  PR interval of ≤ 210 msec;&#xD;
&#xD;
                    -  Electrocardiogram morphology consistent with healthy cardiac ventricular&#xD;
                       conduction and normal rhythm, and with measurement of the QT interval;&#xD;
&#xD;
                    -  No family history of short or long QT syndrome;&#xD;
&#xD;
                    -  No history of risk factors for torsade de pointes or the diagnosis;&#xD;
&#xD;
               7. Female participants must:&#xD;
&#xD;
                    1. Be of nonchildbearing potential ie, surgically sterilized (hysterectomy,&#xD;
                       bilateral salpingectomy, bilateral oophorectomy at least 6 weeks before&#xD;
                       screening) or postmenopausal (where postmenopausal is defined as no menses&#xD;
                       for 12 months without an alternative medical cause), or&#xD;
&#xD;
                    2. If of childbearing potential, must have a negative pregnancy test at&#xD;
                       screening (blood test) and before the first study drug administration (Day&#xD;
                       -1 urine test). They must agree not to attempt to become pregnant, must not&#xD;
                       donate ova, and must use a highly effective contraceptive method from&#xD;
                       signing the consent form until at least 30 days after the last dose of study&#xD;
                       drug.&#xD;
&#xD;
               8. Male participants, if not surgically sterilized, must be willing not to donate&#xD;
                  sperm and, if engaging in sexual intercourse with a female partner who could&#xD;
                  become pregnant, must be willing to use a condom in addition to having the female&#xD;
                  partner use a highly effective contraceptive method from signing the consent form&#xD;
                  until at least 90 days after the last dose of study drug;&#xD;
&#xD;
               9. Have suitable venous access for blood sampling;&#xD;
&#xD;
              10. Be willing and able to comply with all study assessments and adhere to the&#xD;
                  protocol schedule and restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers will be excluded from Part A or Part B of the study if there is&#xD;
             evidence of any of the following at screening, Day -1 or predose on Day 1:&#xD;
&#xD;
               1. History or presence of significant cardiovascular, pulmonary, hepatic, renal,&#xD;
                  hematological, gastrointestinal, endocrine, immunologic, dermatologic or&#xD;
                  neurological disease, including any acute illness or surgery within the past 3&#xD;
                  months determined by the PI to be clinically relevant;&#xD;
&#xD;
               2. Current infection that requires antibiotic, antifungal, antiparasitic or&#xD;
                  antiviral medications;&#xD;
&#xD;
               3. Any history of malignant disease in the last 10 years (excludes surgically&#xD;
                  resected skin squamous cell or basal cell carcinoma);&#xD;
&#xD;
               4. Presence of clinically relevant immunosuppression from, but not limited to,&#xD;
                  immunodeficiency conditions such as common variable hypogammaglobulinemia;&#xD;
&#xD;
               5. Use of or plans to use systemic immunosuppressive (eg, corticosteroids,&#xD;
                  methotrexate, azathioprine, cyclosporine) or immunomodulating medications (eg,&#xD;
                  interferon) during the study or within 4 months prior to the first study drug&#xD;
                  administration;&#xD;
&#xD;
               6. Liver function test results (ie, aspartate aminotransferase [AST], alanine&#xD;
                  aminotransferase [ALT], and gammaglutamyl transferase [GGT]) and total bilirubin&#xD;
                  must not be elevated more than 1.2-fold above the upper limit of normal (ULN);&#xD;
&#xD;
               7. Positive test results for active human immunodeficiency virus (HIV), hepatitis B&#xD;
                  surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies (Abs);&#xD;
&#xD;
               8. History of active, latent or inadequately treated tuberculosis infection;&#xD;
&#xD;
               9. Presence or having sequelae of gastrointestinal, liver, kidney, or other&#xD;
                  conditions known to interfere with the absorption, distribution, metabolism, or&#xD;
                  excretion of drugs;&#xD;
&#xD;
              10. Estimated creatinine clearance (CrCl) &lt; 40 mL/min using the Cockcroft-Gault&#xD;
                  formula or serum creatinine more than 1.5-fold above the ULN;&#xD;
&#xD;
              11. History of substance abuse or alcohol abuse within 12 months prior to first study&#xD;
                  drug administration;&#xD;
&#xD;
              12. Positive drug or alcohol test results;&#xD;
&#xD;
              13. Use of any prescription or over-the-counter medication (including herbal&#xD;
                  products, diet aids, and hormone supplements) within 10 days or 5 half-lives of&#xD;
                  the medication (whichever is longer) prior to the first study drug&#xD;
                  administration, except occasional use of paracetamol;&#xD;
&#xD;
              14. Demonstrated clinically significant (required intervention, eg, emergency room&#xD;
                  visit, epinephrine administration) allergic reactions (eg, food, drug, or atopic&#xD;
                  reactions, asthmatic episodes) which, in the opinion of the investigator, would&#xD;
                  interfere with the volunteer's ability to participate in the trial;&#xD;
&#xD;
              15. Known hypersensitivity to any of the study drug ingredients;&#xD;
&#xD;
              16. Use of any live vaccinations within 30 days prior to the first study drug&#xD;
                  administration except for the influenza vaccine;&#xD;
&#xD;
              17. For women of childbearing potential, a positive serum pregnancy test at screening&#xD;
                  or a positive urine pregnancy test with confirmatory serum pregnancy test on Day&#xD;
                  -1;&#xD;
&#xD;
              18. Donation of blood or plasma within 30 days prior to first study drug&#xD;
                  administration, or loss of whole blood of more than 500 mL within 30 days prior&#xD;
                  to randomization, or receipt of a blood transfusion within 1 year of first study&#xD;
                  drug administration;&#xD;
&#xD;
              19. Participation in another investigational clinical trial within 60 days prior to&#xD;
                  the first study drug administration;&#xD;
&#xD;
              20. Any other condition or prior therapy that in the opinion of the PI would make the&#xD;
                  volunteer unsuitable for this study, including inability to cooperate fully with&#xD;
                  the requirements of the study protocol or likelihood of noncompliance with any&#xD;
                  study requirements;&#xD;
&#xD;
              21. Is an employee of an investigator or sponsor or an immediate relative of an&#xD;
                  investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West China Hospital SiChuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ke Yao</last_name>
      <phone>18980007228</phone>
      <email>yaok@haisco.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 18, 2020</study_first_submitted>
  <study_first_submitted_qc>December 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FTP-198</keyword>
  <keyword>IPF</keyword>
  <keyword>health</keyword>
  <keyword>phase I</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

